Synthesis of new exenatide analogs and investigation of their influence on glycemia and renal function in rats
https://doi.org/10.14341/probl201157342-47
Abstract
New analogs of exenatide with amino acid substitutions at 14, 35, and 39 have been synthesized. They were shown to be more stable than original exenatide in aqueous solutions. In vivo testing on rat models of glucose loading showed that exenatide and its novel analogs possess hypoglycemic activity and stimulate renal excretion of sodium and magnesium ions and osmotically free water but have virtually no effect on the elimination of potassium ions. Experiments with isolated skin and urinary bladder preparations from male frogs showed that exenatide and its analogs promote biosynthesis of physiologically active compounds modulating renal functions.
About the Authors
A E BogolepovaA V Kutina
A S Marina
S K Nikol'skaia
E I Shakhmatova
M I Titov
Iu V Natochin
References
1. Hargrove D.M., Nardone N.A., Persson L.M. et al. Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration. Metabolism 1995;44:9:1231-1237.
2. Holst J.J., Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. AJP-Endo 2004;287:199-206.
3. Degn K.B., Brock B., Juhl C.B. et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and couterregulation during hypoglycemia. Diabetes 2004;53:9:2397-2403.
4. Neumiller J.J. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Ass 2003;2009:49:Suppl 1:S16-S29.
5. Kolterman O.G., Buse J.B., Fineman M.S. et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003;88:7:3082-3089.
6. Викулова О.К., Шестакова М.В. Миметик инкретинов эксенатид - новый препарат для лечения сахарного диабета 2-го типа. Сonsilium Medicum 2006;8:9:113-118.
7. Gutzwiller J.P., Drewe J., Göke B. et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999;276:5:Pt 2:R1541-R1544.
8. Gutzwiller J.P., Hruz P., Huber A.R. et al. Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. Digestion 2006;73:2-3:142-150.
9. Hargrove D.M., Kendall E.S., Reynolds J.M. et al. Biological activity of AC3174, a peptide analog of exendin-4. Regul Pept 2007;141:1-3:113-119.
10. Natochin Y.V., Parnova R.G., Shakhmatova E.I. et al. AVP-independent high osmotic water permeability of frog urinary bladder and autacoids. Pflügers Arch 1996;433:1-2:136-145.
11. Bryson N. WIPO Patent Application WO/2008/116294 Exendin analogs. Matregen Corp (СA), Bryson N. (CA); CA2008/000537; Fil. date Mar 20, 2008; Pub. date Oct 02, 2008. Priority Mar, 23, 2007 № 60/896,584. C07K14/575; A61K38/26. 36 p. URL: http://www.sumobrain.com/patents/wipo/Exendin-analogs/WO2008116294.html.
Review
For citations:
Bogolepova A.E., Kutina A.V., Marina A.S., Nikol'skaia S.K., Shakhmatova E.I., Titov M.I., Natochin I.V. Synthesis of new exenatide analogs and investigation of their influence on glycemia and renal function in rats. Problems of Endocrinology. 2011;57(3):42-47. (In Russ.) https://doi.org/10.14341/probl201157342-47
Views:
414
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
